NovaCardia, Inc. clinical trials
Acquired by Merck & Co., Inc, Sep 2007 · source ↗
The registry lists 6 studies whose lead sponsor is NovaCardia, Inc. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 9, 2009.
- 6studies on the registry
- 0open to participants now
Before and after it joined Merck & Co., Inc
- First submitted before NovaCardia, Inc. became part of Merck & Co., Inc
- 5
- First submitted after NovaCardia, Inc. became part of Merck & Co., Inc
- 1
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs NovaCardia, Inc.’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- rolofylline3 in phase 30 open · 4
All 6 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Completed6100%
Over the years
- 107
- 08
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 5 started before 2007. 2026 so far in the lighter column.
Registry sponsor names on this page
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)6 studies
Something wrong with this grouping? Tell us on the Merck & Co., Inc page.
Studies
Recruiting first, then most recently updated. Showing 6 of 6. All Merck & Co., Inc studies →
- PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal FunctionCompletedNCT00328692Phase 3
Sponsor listed in the registry: NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before NovaCardia, Inc. became part of Merck & Co., Inc
- PROTECT-2: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect on Congestion and Renal FunctionCompletedNCT00354458Phase 3
Sponsor listed in the registry: NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before NovaCardia, Inc. became part of Merck & Co., Inc
- Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV TherapyCompletedNCT00443690Phase 3
Sponsor listed in the registry: NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before NovaCardia, Inc. became part of Merck & Co., Inc
- Effects of MK7418 on Diuresis and Renal Function in Congestive Heart Failure PatientsCompletedNCT00652782Phase 2
Sponsor listed in the registry: NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted after NovaCardia, Inc. became part of Merck & Co., Inc
- Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).CompletedNCT00159627Phase 2
Sponsor listed in the registry: NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before NovaCardia, Inc. became part of Merck & Co., Inc
- Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal ImpairmentCompletedNCT00159614Phase 2
Sponsor listed in the registry: NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · First submitted before NovaCardia, Inc. became part of Merck & Co., Inc